D. Boral Capital Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $25.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 442.30% from the company’s current price.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Benchmark increased their price target on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Trading Down 1.5 %

NASDAQ HUMA opened at $4.61 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The firm has a 50-day moving average price of $4.67 and a 200 day moving average price of $5.69. The stock has a market capitalization of $580.21 million, a P/E ratio of -3.44 and a beta of 1.32. Humacyte has a 52-week low of $2.48 and a 52-week high of $9.97.

Insider Transactions at Humacyte

In other news, CEO Laura E. Niklason sold 811,172 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Concurrent Investment Advisors LLC acquired a new stake in shares of Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. bought a new stake in Humacyte during the 2nd quarter valued at $83,000. FORA Capital LLC bought a new stake in Humacyte during the 3rd quarter valued at $96,000. Profund Advisors LLC bought a new position in shares of Humacyte in the second quarter worth $97,000. Finally, Insigneo Advisory Services LLC acquired a new position in shares of Humacyte during the third quarter valued at $109,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.